Bovi-Shield GOLD FP 5 VL5 (Canada)

Bovine Rhinotracheitis-Virus Diarrhea-Parainfluenza-3-Respiratory Syncytial Virus Vaccine

Modified Live Virus

Campylobacter Fetus-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin

Bovi-Shield GOLD FP 5 VL5 Indications

Bovi-Shield GOLD FP 5 VL5 is for vaccination of healthy cows and heifers prior to breeding to prevent persistently infected calves caused by bovine virus diarrhea (BVD) virus Types 1 and 2 and as an aid in preventing abortion caused by infectious bovine rhinotracheitis (IBR, bovine herpesvirus Type 1) virus; respiratory disease caused by IBR, BVD Types 1 and 2, parainfluenza-3 (PI-3) and bovine respiratory syncytial virus (BRSV); BVD Type 2 testicular infection; campylobacteriosis (vibriosis) caused by Campylobacter fetus; and leptospirosis caused by Leptospira canicola, L. grippotyphosa, L. hardjo, L. icterohaemorrhagiae, and L. pomona. A 12-month duration of immunity has been demonstrated against IBR-induced abortion and persistently infected calves caused by BVD Types 1 and 2. Bovi-Shield GOLD FP 5 VL5 may be administered to pregnant cattle provided they were vaccinated, according to label directions, with any Bovi.Shield GOLD FP vaccine within the past 12 months. Bovi-Shield GOLD FP 5 VL5 may also be administered to calves nursing pregnant cows provided their dams were vaccinated within the past 12 months as described above. To help ensure safety in pregnant cattle, cows and heifers must receive at least 2 doses of any Bovi-Shield GOLD FP product as non-pregnant animals with the first dose administered after 6 months of age and the second dose administered approximately 30 days prebreeding.

PRODUCT DESCRIPTION: The freeze-dried vaccine is a preparation of modified live virus (MLV) strains of IBR, BVD (Types 1 and 2), PI-3, and BRSV. The Campylobacter bacterin is an inactivated suspension of C. fetus. It is combined with an inactivated Leptospira bacterin prepared from whole cultures of the agents indicated. The Campylobacter-Leptospira bacterin is supplied as a diluent for the IBR-BVD-PI-3-BRSV vaccine.

Directions For Use

General Directions: Vaccination of healthy cattle is recommended. Aseptically rehydrate the freeze-dried vaccine with the liquid bacterin provided, shake well, and administer 2 mL intramuscularly. In accordance with Beef Quality Assurance guidelines, this product should be administered in the muscular region of the neck.

Primary Vaccination: Administer a single 2-mL dose to all breeding cows and heifers approximately 1 month prior to breeding or being added to the herd, followed by a single dose of Vibrio/Leptoferm-5™ 3-4 weeks later.

Revaccination: Annual revaccination with a single dose of Bovi-Shield GOLD FP 5 VL5 is recommended.

Good animal husbandry and herd health management practices should be employed.

Precautions

Do not use in pregnant cows (abortions can result) unless they were vaccinated, according to label directions, with any Bovi-Shield GOLD FP vaccine within the past 12 months. Do not use in calves nursing pregnant cows unless their dams were vaccinated within the past 12 months as described above. Do not vaccinate calves under 3 months of age.

To help ensure safety in pregnant cattle, cows and heifers must receive at least 2 doses of any Bovi-Shield GOLD FP product as non-pregnant animals with the first dose administered after 6 months of age and the second dose administered approximately 30 days prebreeding.

Store at 2°-8°C. Prolonged exposure to higher temperatures and/or direct sunlight may adversely affect potency. Do not freeze.

Use entire contents when first opened.

Sterilized syringes and needles should be used to administer this vaccine. Do not sterilize with chemicals because traces of disinfectant may inactivate the vaccine.

Burn containers and all unused contents.

Do not vaccinate within 21 days before slaughter.

Contains gentamicin and thimerosal as preservatives.

Vaccination of stressed animals should be delayed.

Occasional hypersensitivity reactions may occur up to 18 hours postvaccination. Owners should be advised to observe animals during this period. While this event appears to be rare overall, dairy cattle may be affected more frequently than other cattle. Animals affected may display excessive salivation, incoordination, and/or dyspnea. Animals displaying such signs should be treated immediately with epinephrine or equivalent. In nonresponsive animals, other modes of treatment should be considered. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy.

This product has been shown to be efficacious in healthy animals. A protective immune response may not be elicited if animals are incubating an infectious disease, are malnourished or parasitized, are stressed due to shipment or environmental conditions, are otherwise immunocompromised, or the vaccine is not administered in accordance with label directions.

Technical inquiries should be directed to Zoetis Inc. Veterinary Services, (800) 461-0917.

For veterinary use only.

U.S. Veterinary License No. 190

Zoetis Inc., Kalamazoo, MI 49007, USA

50667100

Presentation: 10 and 50 dose vials.

CPN: 1198318.5